Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA, Riely GJ
Clin Cancer Res. 2011 17 (8): 2521-7

PMID: 21248303 · DOI:10.1158/1078-0432.CCR-10-2662

MeSH Terms (21)

Adenocarcinoma Adenocarcinoma of Lung Aged Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Cetuximab Dose-Response Relationship, Drug Drug Administration Schedule Drug Resistance, Neoplasm ErbB Receptors Erlotinib Hydrochloride Exanthema Fatigue Female Humans Lung Neoplasms Male Middle Aged Quinazolines Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: